OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
195158

Jinxin Fertility Group Ltd

Healthcare Facilities & ServicesVerified

Jinxin Fertility Group Ltd has a debt-to-equity ratio of 0.32, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.87, suggesting that it may face challenges in meeting short-term obligations without additional cash flow or asset liquidation. The company's profitability is underperforming, with a return on equity of -10.68% and a return on assets of -6.99%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a concern for investors and stakeholders. Jinxin Fertility Group Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This concentration increases the company's exposure to sector-specific risks and limits its ability to offset losses in one area with gains in another. The company's growth trajectory is mixed. While it reported a net loss of CNY 976.15 million for the period, it also generated operating cash flow of CNY 588.89 million. The negative net income and free cash flow suggest that the company is investing heavily in operations or facing high costs, which could impact its ability to sustain growth in the near term. The risk assessment highlights a key flag: the company's net cash position is negative after subtracting total debt. This indicates that the company's cash reserves are insufficient to cover its debt obligations, which could lead to liquidity constraints. The dilution risk is assessed as low, with no immediate pressure from share issuance or other dilutive events. Recent events include analyst estimates that suggest a range of price targets from CNY 2.30 to CNY 4.57, with a mean recommendation of 2.25, indicating a generally positive outlook from analysts. However, the company's financial performance and liquidity position may influence the accuracy of these projections.

30-day price · 1951-0.20 (-8.0%)
Low$2.27High$2.53Close$2.30As of20 May, 00:00 UTC
Profile
CompanyJinxin Fertility Group Ltd
Ticker1951.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Jinxin Fertility Group Ltd provides fertility services and operates in the healthcare facilities and services industry, generating revenue primarily through medical treatments and procedures related to reproductive health.

Classification. Jinxin Fertility Group Ltd is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

Jinxin Fertility Group Ltd has a debt-to-equity ratio of 0.32, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.87, suggesting that it may face challenges in meeting short-term obligations without additional cash flow or asset liquidation. The company's profitability is underperforming, with a return on equity of -10.68% and a return on assets of -6.99%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a concern for investors and stakeholders. Jinxin Fertility Group Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This concentration increases the company's exposure to sector-specific risks and limits its ability to offset losses in one area with gains in another. The company's growth trajectory is mixed. While it reported a net loss of CNY 976.15 million for the period, it also generated operating cash flow of CNY 588.89 million. The negative net income and free cash flow suggest that the company is investing heavily in operations or facing high costs, which could impact its ability to sustain growth in the near term. The risk assessment highlights a key flag: the company's net cash position is negative after subtracting total debt. This indicates that the company's cash reserves are insufficient to cover its debt obligations, which could lead to liquidity constraints. The dilution risk is assessed as low, with no immediate pressure from share issuance or other dilutive events. Recent events include analyst estimates that suggest a range of price targets from CNY 2.30 to CNY 4.57, with a mean recommendation of 2.25, indicating a generally positive outlook from analysts. However, the company's financial performance and liquidity position may influence the accuracy of these projections.
Key takeaways
  • Jinxin Fertility Group Ltd has a conservative capital structure with a debt-to-equity ratio of 0.32.
  • The company is currently unprofitable, with a return on equity of -10.68% and a return on assets of -6.99%.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • Analysts have a generally positive outlook, with a mean price target of CNY 3.25 and a mean recommendation of 2.25.
  • The company's liquidity position is medium, with a current ratio of 0.87, indicating potential short-term financial constraints.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$2.65B
Gross profit$886.5M
Operating income-$923.5M
Net income-$976.1M
R&D
SG&A
D&A
SBC
Operating cash flow$588.9M
CapEx-$264.5M
Free cash flow-$902.3M
Total assets$13.96B
Total liabilities$4.82B
Total equity$9.14B
Cash & equivalents
Long-term debt$2.96B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$9.14B
Net cash-$2.96B
Current ratio0.9
Debt/Equity0.3
ROA-7.0%
ROE-10.7%
Cash conversion-60.0%
CapEx/Revenue-10.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric1951Activity
Op margin-34.9%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin-36.8%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin33.5%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-10.0%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity32.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Mean price target3.25 CNY
Median price target3.15 CNY
High price target4.57 CNY
Low price target2.30 CNY
Mean recommendation2.25 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count5.00
Hold count2.00
Sell count2.00
Strong-sell count0.00
Mean EPS estimate0.09 CNY
Last actual EPS0.08 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 23:32 UTCJob: eed48917